Teva facing EU fine for disparaging Copaxone rival: report
by
Contributor since / Followers
Contributor since / Followers
2 months ago
Mlenny
- Teva (NYSE:TEVA) is facing a fine by EU regulators for allegedly disparaging a product that competes with its multiple sclerosis drug Copaxone, according to Reuters.
- Reuters said the move highlights the EU’s concern that such practices undermine competition in the pharmaceutical industry. It noted that the company was charged by the European Commission in 2022 for engaging in anticompetitive practices over Copaxone.
- The European Commission declined to comment on the matter, while Teva did not immediately respond to requests for comment, Reuters added.